Le Lézard
Classified in: Health
Subject: AWD

Top NYC Vascular Surgeon, Dr. Alan Benvenisty, Earns Prestigious Lifetime Achievement Award


Dr. Benvenisty is the Site Chief of Surgery/Mount Sinai Morningside, specializing in vascular surgery and endovascular surgery, and is qualified as a registered vascular technologist (RVT).

NEW YORK, May 9, 2024 /PRNewswire-PRWeb/ -- Renowned vascular surgeon Dr. Alan Benvenisty has been awarded the esteemed Lifetime Achievement Award by the Mount Sinai Faculty Council. The much-anticipated awards ceremony, scheduled to take place virtually on May 13th, 2024, will honor Dr. Benvenisty's remarkable accomplishments. The council has recognized his exceptional contributions to the field of vascular surgery, which has set him apart from a highly competitive group of nominees. His expertise extends beyond his conservative approach to treatment and intervention. With extensive experience in renal transplant surgery, carotid procedures, aneurysm repairs and limb bypass surgeries, he has become a trusted specialist in the field. However, what truly sets Dr. Alan Benvenisty apart is his commitment to personalized patient care. Recognizing that each patient and circumstance is unique, he firmly believes in tailoring treatment plans to suit individual needs. For patients suffering from renal failure, kidney disease, blood clots, aneurysms and other vascular illnesses, Dr. Benvenisty strives to provide the least invasive options, utilizing non-surgical methods whenever possible. With a strong commitment to excellence and patient-centered care, he has earned the respect and admiration of both his peers and patients alike. As he continues to push the boundaries of vascular surgery, his impact on the medical community is undeniable.

"I am honored to receive the Lifetime Achievement Award from the Mount Sinai Faculty Council. This recognition serves as a testament to the dedication and passion I have for my patients and the field of vascular surgery," says Dr. Alan Benvenisty.

"I am honored to receive the Lifetime Achievement Award from the Mount Sinai Faculty Council. This recognition serves as a testament to the dedication and passion I have for my patients and the field of vascular surgery," says Dr. Alan Benvenisty.

More About Alan Benvenisty M.D.:

Dr. Alan I. Benvenisty graduated from the College of Physicians and Surgeons of Columbia University, where he remained to complete his internship and residency in general surgery. Selected as "Super Chief," he completed his fellowship in vascular and transplant surgery and was invited to join the staff at The Presbyterian Hospital. During his eighteen-year tenure, he became a respected member of the faculty of the College of Physicians and Surgeons and was later promoted to professor of clinical surgery. Dr. Benvenisty a respected member of several surgical societies, including being one of the few vascular surgeons in the American Society of Transplant Surgeons. Recognized by Castle Connolly as one of New York and America's Top Doctors, Dr. Benvenisty's contribution and work with patients has been presented in numerous newspaper articles and featured on national news programs. For more information about the treatments offered by Dr. Benvenisty, please call his New York City office at (212) 523-4706 or visit http://www.drbenvenisty.com.

Media Contact

Dr. Alan Benvenisty, Alan Benvenisty M.D., (212) 523-4706, [email protected], https://www.drbenvenisty.com/

SOURCE Alan Benvenisty M.D.


These press releases may also interest you

at 04:45
ERS Genomics Limited (?ERS'), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS' CRISPR/Cas9 patent portfolio....

at 03:15
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly...

at 02:30
Ahead of International Tea Day - 21st May 2024  - and with summer inspiring more of us to get off the sofa to be active, a 2024 real-world research study1 reviewed by the tea science experts at the Tea Advisory Panel ? www.teaadvisorypanel.com -...

at 02:30
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....



News published on and distributed by: